** Drug developer Protagonist Therapeutics' PTGX.O shares rise 3.1% to $39.68
** Company posts Q4 adj profit of $1.98 per share, beating analysts' estimates of 32 cents per share, according to data compiled by LSEG
** The company got a $165 million milestone payment during Q4 2024 after it entered into a license and collaboration agreement with Johnson & Johnson JNJ.N for skin disease drug icotrokinra in November 2024
** PGTX expects to release late-stage study results of blood cancer treatment rusfertide in collaboration with Takeda Pharmaceutical 4502.T in March 2025
** In the last 12 months, PTGX has risen 41.4%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.